Thermo Fisher Scientific’s Biomarker B-R-A-H-M-S PCT (Procalcitonin) Included in S3 Guidelines

HENNIGSDORF, Germany - Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its biomarker, B-R-A-H-M-S PCT (procalcitonin), has been included in the new set of guidelines published by the Association of Scientific Medical Societies in Germany (AWMF). This consensus document, the S3 guideline for epidemiology, diagnostics, anti-microbial therapy and management of adult patients with community-acquired lower respiratory tract infections and pneumonia, designates PCT as an inflammatory biomarker that helps better control antibiotic therapy. Thermo Fisher will apply the findings to its specialty diagnostics research.

“The inclusion of PCT in the AWMF guidelines will help reduce the unnecessary administration of antibiotics and, as a result, improve the efficacy of antibiotics when they do need to be used,” said Dr. Andreas Bergmann, Chief Research Officer of B-R-A-H-M-S AG. “Developments like these are a critical step towards more accurate diagnoses and effective use of health care resources.”

In a normal metabolism, PCT is produced in the thyroid gland and helps regulate the calcium and phosphate balance in the body. The results of a recent, multi-centric, randomised study involving 1,359 patients demonstrate that a systematic introduction of PCT can reduce the administration of antibiotics to a third and result in fewer antibiotic prescriptions and side effects. The PCT biomarker is particularly effective with chronic obstructive pulmonary diseases (COPD) and community-acquired pneumonia (CAP).

B-R-A-H-M-S products include specialty in-vitro diagnostic tests based on patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening. B-R-A-H-M-S AG was acquired by Thermo Fisher Scientific in October 2009.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, we have approximately 34,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

Media Contact Information: Ingo Buchholzer Phone: +49-(0)3302-883-637 E-mail: ingo.buchholzer@thermofisher.com

www.procalcitonin.com

www.brahms.com

www.thermofisher.com

Source: Thermo Fisher Scientific

Media Contact Information: Ingo Buchholzer, Phone: +49-(0)3302-883-637, E-mail: ingo.buchholzer at thermofisher.com